

TITLE PAGE
- Food Science of Animal Resources -

ARTICLE INFORMATION	Fill in information in each box below
Article Type	Research article
Article Title	Application of conjugated linoleic acid-producing strain, <i>Bifidobacterium breve</i> JKL2022, in the development of probiotic dairy products
Running Title	Development of probiotic dairy products with <i>Bifidobacterium breve</i> JKL2022
Author(s)	Yujin Jang, Arxel G. Elnar, Mo Hyeon Kang, and Geun-Bae Kim*
Affiliation(s)	Department of Animal Science and Technology, Chung-Ang University, Anseong 17546, Korea
Special Remarks	
ORCID	Yujin Jang (https://orcid.org/0009-0001-4956-3774) Arxel G. Elnar (https://orcid.org/0000-0002-2716-4924) Mo Hyeon Kang (https://orcid.org/0009-0007-4734-7385) Geun-Bae Kim (https://orcid.org/0000-0001-8531-1104)
Conflicts of Interest	The authors declare no potential conflict of interest.
Acknowledgements	This research was supported by the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Science and ICT (2021R1A2C1093838). This research was also supported by a Chung-Ang University Graduate Research Scholarship (Academic Scholarship for College of Biotechnology and Natural Resources) in 2023.
Author Contributions	Conceptualization: Kim GB Data curation: Jang YJ Formal analysis: Jang YJ, Elnar AG, Kang MH, Kim GB Methodology: Jang YJ, Elnar AG, Kang MH, Kim GB Software: Jang YJ, Elnar AG, Kim GB Validation: Kim GB Investigation: Jang YJ, Elnar AG Writing - original draft: Jang YJ, Elnar AG Writing - review & editing: Jang YJ, Elnar AG, Kang MH, Kim GB
Ethics Approval	This article does not require IRB/IACUC approval because there are no human and animal participants.

CORRESPONDING AUTHOR CONTACT INFORMATION

For the <u>corresponding</u> author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Geun-Bae, Kim
Email address – this is where your proofs will be sent	kimgeun@cau.ac.kr
Secondary Email address	
Postal address	Department of Animal Science and Technology, Chung-Ang University, Anseong 17546, Korea
Cell phone number	+82-10-7225-5986
Office phone number	+82-31-670-3027
Fax number	+82-31-676-5986

2 **Application of conjugated linoleic acid-producing strain, *Bifidobacterium breve***
3 **JKL2022, in the development of probiotic dairy products**

5 Abstract

6 With the rising interest in functional foods, several studies have developed food products
7 with additional health benefits, particularly through supplementation with probiotics. The
8 present study assessed the potential of *Bifidobacterium breve* JKL2022 as a probiotic adjunct
9 culture in dairy products. Preliminary experiments on the capacity of JKL2022 to grow and
10 produce conjugated linoleic acid (CLA) in dairy products were performed using 10%
11 reconstituted skim milk (RSM). Thereafter, the survivability of *B. breve* JKL2022 in three
12 dairy products (whole milk, yogurt, and cream cheese) and its biochemical effects on each
13 product were investigated. The results revealed that the growth, fermentation, and CLA
14 production of *B. breve* JKL2022 were significantly enhanced in 10% RSM supplemented with
15 either 0.1% yeast extract or 0.1% yeast extract with 2.0% glucose compared with those of the
16 control. Additionally, JKL2022 remained viable above the minimum probiotic standard ($> 10^6$
17 CFU/mL) in whole milk and cream cheese during 15 d of refrigerated storage. The viability of
18 *B. breve* JKL2022 was greater in yogurts supplemented with glucose, inulin, and trans-
19 galactooligosaccharides (TOS) than in the control. However, it exhibited the lowest
20 survivability (range: 2.26–4.55 log CFU/mL) in yogurt after 15 d of refrigerated storage,
21 indicating the sensitivity of *B. breve* JKL2022 to acidic conditions. Overall, this study
22 suggests that developing probiotic or CLA-enhanced dairy products using *B. breve* JKL2022
23 is possible. In particular, it is reasonably suitable for developing probiotic cheeses that have a
24 high pH and buffering capacity.

25 Keywords: functional foods, *Bifidobacterium breve*, probiotic dairy products, conjugated
26 linoleic acid, adjunct culture

27 INTRODUCTION

28 The demand for functional foods has recently escalated, as food consumption has
29 increasingly focused on gaining additional health benefits than simply managing energy
30 intake. This trend has been intricately linked to technological development, the growing aging
31 population, and an emphasis on immunity (Ali et al., 2022). Among the several functional
32 ingredients, probiotics are recognized for their health benefits, including enhancing nutritional
33 value, managing cholesterol levels, improving immunity, and mitigating the risk of colon
34 cancer (Zendeboodi et al., 2020). As numerous studies have highlighted the benefits of
35 probiotics, multiple researchers have focused on developing functional foods that incorporate
36 these beneficial microorganisms (Misra et al., 2021).

37 Among the most commonly used probiotic species, *Bifidobacterium* spp. are well-known to
38 be “Generally Recognized as Safe.” They play a crucial role in the human intestinal
39 microbiota, offering various functional benefits, such as lactose digestibility, anti-
40 carcinogenic activity, cholesterol level reduction, vitamin B synthesis, and calcium absorption
41 (Mysore Saiprasad et al., 2023; Abdi et al., 2022; Barone et al., 2022; Faghfoori et al., 2021;
42 Uebanso et al., 2020). Among the diverse functionalities of *Bifidobacterium*, research on
43 conjugated linoleic acid (CLA) production has actively been conducted (Gao et al., 2020).
44 CLA is recognized for its numerous health advantages as a functional ingredient, such as its
45 anti-carcinogenic, anti-atherosclerotic, anti-obesity, and anti-inflammatory properties (Basak
46 and Duttaroy, 2020). Because of these health benefits, research into developing probiotic
47 foods with enhanced CLA content using *Bifidobacterium* spp. is currently underway (Mei et
48 al., 2022).

49 However, *Bifidobacterium* spp. encounter several challenges during production because of
50 their anaerobic nature and poor resistance to low pH, rendering it difficult to maintain
51 minimum viable cell counts of 10^6 – 10^7 CFU/mL or g, as required for probiotic foods (He et

52 al., 2023; Gao et al., 2021; Terpou et al., 2019). As a solution, the application of
53 bifidobacteria to dairy products has been proposed. Dairy products are well-known probiotic
54 carriers as they possess a high buffering capacity, which helps protect probiotics during
55 passage through the human gastrointestinal tract (Vivek et al., 2023). Additionally, the
56 incorporation of probiotic bacteria into dairy products offers a natural means of delivering
57 these microorganisms to consumers.

58 Among dairy products, fermented milk is a common probiotic carrier; however, its low pH
59 (< 4.6) would have negatively affected *Bifidobacterium* survival by the time it reaches
60 consumers. In contrast, cheese provides a more favorable environment with a higher pH and
61 solid content, rendering it a preferred carrier (Rolim et al., 2020). Therefore, this study aimed
62 to evaluate CLA production by *B. breve* JKL2022 in reconstituted skim milk (RSM). Further,
63 the study assessed the survivability of *B. breve* JKL2022 in three representative dairy
64 products: whole milk, yogurt, and cream cheese along with its chemical characteristics.
65 Ultimately, this study evaluated the potential of *B. breve* JKL2022 as a CLA-producing
66 probiotic adjunct culture for dairy products.

67 MATERIALS AND METHODS

68 Growth Profile and CLA Conversion of *B. breve* JKL2022 in RSM

69 *B. breve* JKL2022 used in this paper is registered in the Korean Agricultural Culture
70 Collection (KACC) as *B. breve* KACC 81214BP. The ability of *B. breve* JKL2022 to convert
71 linoleic acid (LA) to CLA in RSM broth was evaluated. Briefly, 10% (v/v) skimmed milk
72 powder (SMP) was prepared in distilled water and supplemented with various combinations
73 of glucose and yeast extract, as listed in **Table 1**. The modified RSM broths were sterilized in
74 an autoclave (121°C, 15 psi, for 15 min) or via heat treatment (90–95°C for 10 min), followed
75 by cooling in the ice bath. Thereafter, all media were supplemented with 0.50 mg/mL LA
76 before inoculating a 1.0% (v/v) overnight culture of *B. breve* JKL2022.

77 The cultures were incubated under aerobic and **anaerobic conditions** at 37°C for 12–24 h.
78 After incubation, pH, viable cell count, and CLA production were measured. The pH of each
79 treatment was measured using a BP3001 Benchtop pH meter (Trans Instruments, Singapore).
80 The viable cell count was determined by plating on de Man, Rogosa, and Sharpe agar (Difco,
81 USA) with 0.05% L-cysteine hydrochloride. The plates were incubated at 37°C for 24 hours
82 under anaerobic conditions using the GasPak™ system (BD, Dickinson) and the results were
83 reported as log CFU/mL. CLA concentration was determined using the isopropanol–hexane
84 extraction protocol, with minor modifications (Jung et al., 2006). Briefly, 400 µL of culture
85 was transferred to a sterile 2.0-mL microfuge tube, followed by the sequential addition of 800
86 µL of isopropanol (Sigma, USA) and 600 µL of hexane (Sigma, USA). The mixture was
87 vortexed for 5 min, followed by centrifugation (980 × g, 5 min, 20°C) to facilitate phase
88 separation. The hexane layer (top layer) containing the conjugated fatty acids was diluted in
89 methanol (Sigma, USA) in a 100:900 ratio (v:v) before measuring absorbance at 233 nm
90 using a UV-transparent 96-well plate (UVMax™, SPL, Korea). All optical density (OD)

91 readings were performed using an INNO Spectrophotometer (INNO, LTEK Co., Ltd, Korea).

92

93 Manufacture of Probiotic Whole Milk, Yogurt, and Cream Cheese

94 Whole milk heat-treated at ultra-high temperature (130°C, 2–5 s) was obtained from a
95 commercial market in Anseong, Gyeonggi-do, Republic of Korea. Subsequently, JKL2022
96 was inoculated into 500 mL of whole milk at 2.01×10^7 CFU/mL and aseptically distributed
97 into 50-mL sterile glass tubes. The samples were stored at 4°C for 15 d.

98 For probiotic yogurt production, the total solid–nonfat content in 3.2 L of whole milk was
99 adjusted to 11% using commercial SMP. Thereafter, the milk was divided into four groups:
100 T1 (control), containing no additional carbohydrates; T2, supplemented with 2% (w/v)
101 glucose (Duksan, Korea); T3, supplemented with 2% (w/v) inulin (Fibrulose® F90, Cosucra,
102 Belgium); and T4, supplemented with trans-galactooligosaccharides (TOS; Oligomate®
103 55NP, Yakult, Japan). All treatments were subsequently heat-treated at 95°C for 10 min and
104 immediately cooled to 40°C in an ice bath. Thereafter, a thermophilic starter culture (TCC-3;
105 Chr. Hansen, Hørsholm, Denmark) containing *Streptococcus thermophilus* and *Lactobacillus*
106 *delbrueckii* subsp. *bulgaricus* as well as JKL2022 was inoculated at 0.01% (w/v) and $2.58 \times$
107 10^7 CFU/mL in all treatments, respectively. Fermentation was conducted in a 37°C water bath
108 until the mixture had reached pH 4.60 (approximately 4–5 h). Subsequently, the yogurt
109 samples were cooled in the ice bath and subjected to the same conditions mentioned above.

110 Probiotic cream cheese was manufactured from 40 L of bovine raw milk obtained from a
111 farm affiliated with Chung-Ang University, Anseong, Gyeonggi-do, Republic of Korea. First,
112 the raw milk was pasteurized at 65°C for 30 min and subsequently cooled to 32°C. Thereafter,
113 the total milk fat content was adjusted to 8% using 6 L of fresh cream (38% fat content).
114 Afterward, a Flora Danica starter culture (Chr. Hansen, Hørsholm, Denmark) comprising
115 *Lactococcus lactis* subsp. *cremoris*, *L. lactis* subsp. *lactis*, *L. lactis* subsp. *diacetylactis*, and

116 *Leuconostoc* spp. was inoculated at 0.03% (w/v) along with 2.45×10^7 CFU/mL of JKL2022.
117 To facilitate curd formation, 0.02% (v/v) rennet Naturen® (92% chymosin, 290 IMCU/mL;
118 Chr. Hansen, New Zealand) was added and incubated for 45 min at 32°C. Subsequently, the
119 curd was cut horizontally and vertically into 1.5-cm cubes and fermented at 32°C until
120 achieving a pH of 5.55. Thereafter, heat treatment was applied at 48°C for 10 min to
121 inactivate the starter culture, and the curds were subsequently placed in cheesecloth, followed
122 by whey drainage at 10°C for 3 h. Finally, the cheese samples were salted at 0.5% (w/w) and
123 subsequently packaged into 220-mL plastic containers. All cheese samples were stored as
124 previously described.

125 JKL2022 viability in cream cheese was measured during both the manufacturing and
126 storage processes. Samples were collected after inoculation, fermentation, heating, and
127 drainage. For microbiological and chemical analyses, all samples from the three dairy
128 matrices were analyzed every 3 days (0, 3, 6, 9, 12, and 15 d) throughout storage.

130 Chemical Analysis

131 To analyze whole milk and yogurt, pH and titratable acidity (TA) were measured, while for
132 cream cheese analysis, pH was measured. To determine the pH of cream cheese, 5-g cheese
133 samples were each mixed with 5 mL of distilled water, and the pH values of the resulting
134 mixtures were measured. The pH values of all three dairy matrices were determined using a
135 pH meter (Trans®, BP3001, Singapore). To measure TA, 0.1% phenolphthalein indicator
136 solution was employed, and 0.1 N NaOH was used to titrate the samples to neutrality. TA was
137 presented as a percentage of samples and calculated using the following formula:

$$138 \quad \text{TA (\%)} = \frac{0.0090 \times \text{volume of NaOH used (mL)}}{\text{Weight of the sample (g)}} \times 100$$

139

140 Microbiological Analysis and Survival Rate (%) Calculation

141 For the microbiological analysis of JKL2022 in whole milk and yogurt, samples were
142 diluted 10-fold using 1× phosphate-buffered saline (PBS). For cream cheese, 2-g cheese
143 samples were homogenized with 18 mL of 1× PBS using a homogenizer (SHG-15D-Set-A;
144 Daihan Scientific, Korea) and diluted in the same manner as previously described. Viable
145 JKL2022 cells were enumerated in TOS–propionate agar (Sigma, USA) supplemented with
146 1% (v/v) mupirocin (Medion, Korea) and incubated at 37°C for 48 h under anaerobic
147 conditions. The survival rate (%) of JKL2022 was calculated using the following formula:

$$148 \quad \text{Survival Rate (\%)} = \frac{\text{Log}(\text{CFU/mL})_{T_n}}{\text{Log}(\text{CFU/mL})_{T_0}} \times 100$$

149 where $\log(\text{CFU/mL})_{T_n}$ is the viable cell count calculated at each storage time point, and \log
150 $(\text{CFU/mL})_{T_0}$ denotes the viable cell count immediately after inoculation.

151

152 Statistical Analysis

153 All experiments were conducted in triplicate within the same batch. The data shown in the
154 Figures and Tables are expressed as the mean \pm standard deviation ($n = 3$). Statistical analysis
155 was performed using GraphPad Prism (version 8.0.1; GraphPad Software, San Diego, CA,
156 USA). For each experiment, statistical analysis involved one-way analysis of variance
157 (ANOVA) and two-way ANOVA, followed by Tukey's test for post-hoc analysis to identify
158 differences between means. Statistical significance was set at $p < 0.05$.

159 RESULTS

160 RSM Broth as a Culture Medium

161 *B. breve* JKL2022 demonstrated the ability to grow and produce CLA in modified RSM
162 medium (**Figure 1**). In terms of fermentation activity measured in terms of pH (Figure 1A)
163 and cell viability measured in terms of CFU/mL (Figure 1B), the addition of 0.1% yeast
164 extract (RSY) favored JKL2022 growth more than 2.0% glucose (RSG) supplementation.
165 Meanwhile, the combination of 0.1% yeast extract and 2.0% glucose (RSGY) did not exhibit
166 higher viability or better fermentation than supplementation with 0.1% yeast extract alone.
167 Notably, media prepared via autoclave displayed significantly lower cell growth ($p < 0.05$)
168 under aerobic (RSY, 8.2 log CFU/mL; RSGY, 7.92 log CFU/mL) than under anaerobic (RSY,
169 9.05 log CFU/mL; RSGY, 9.10 log CFU/mL) conditions, while those prepared via heat
170 treatment yielded a similar viable cell count range ($p > 0.05$) for RSY and RSGY (8.96–9.14
171 log CFU/mL). Generally, incubation under anaerobic conditions enabled better JKL2022
172 proliferation. This observation was consistent regardless of the sterilization method.

173 In terms of CLA production (Figure 1C), JKL2022 exhibited significant CLA conversion
174 when cultured in RSY or RSGY, independent of the sterilization method. Specifically,
175 autoclaved RSY and RSGY under aerobic conditions reached OD₂₃₃ values 0.226 ± 0.175
176 and 0.230 ± 0.159 , while heat-treated media yielded 0.357 ± 0.059 and 0.462 ± 0.014 ,
177 respectively. Moreover, incubation in the same media under anaerobic conditions yielded
178 higher CLA concentrations, reaching OD₂₃₃ 0.638 ± 0.018 and 0.719 ± 0.049 for autoclaved
179 RSY and RSGY, and 0.567 ± 0.003 and 0.615 ± 0.042 for heat-treated media, respectively.
180 The rest of the tested media failed to produce significant CLA during the incubation period.
181 Notably, CLA production was exclusively observed when curd formation occurred during
182 growth, that is, when the pH of the culture medium reached approximately ≤ 5.0 .

183 Chemical Properties and Probiotic Viability of Whole Milk

184 The pH, TA (%), bacterial count, and survivability (%) values of JKL2022 in whole milk
185 during 15-day refrigerated storage are presented in **Figure 2**. The initial pH of whole milk
186 was 6.65, and it gradually decreased to 6.58 after 9 d of refrigerated storage (Figure 2A).
187 Nevertheless, the changes during the 15-day storage period were not statistically significant (p
188 > 0.05). In contrast, TA notably increased to 0.16% at day 9 from an initial value of 0.14%
189 and remained constant until day 15 (Figure 2B, $p < 0.05$). The initial concentration of
190 JKL2022 was 7.55 log CFU/mL and was maintained at 7.46 log CFU/mL up to 15 d of
191 storage (Figure 2C, $p > 0.05$). The calculated survival rate (%) of JKL2022 remained between
192 99% and 100% throughout the 15-d storage period at 4°C (Figure 2D, $p > 0.05$).

193

194 Chemical Properties and Probiotic Viability of Yogurt

195 The pH, TA (%), bacterial count, and survivability (%) values of four different yogurt
196 treatments inoculated with JKL2022 were compared (**Figure 3**). Overall, all treatments
197 displayed significant differences in pH and TA (%) throughout their ripening periods ($p <$
198 0.05). Notably, a substantial decline in pH was observed until day 9 ($p < 0.05$); thereafter, it
199 remained stable for the remainder of the storage period (Figure 3A). Among the four yogurt
200 treatment groups, T2 and T3 exhibited the greatest declines in pH from 4.57 and 4.58 after
201 fermentation (day 0) to 4.27 and 4.30 on day 15 of storage, respectively (Figure 3B). In
202 contrast, T1 and T4 demonstrated relatively smaller declines in pH from 4.59 and 4.56 on day
203 0 to 4.31 and 4.32 on day 15, respectively. Despite the addition of carbohydrates as an extra
204 energy source, T4 yielded a similar pH value to that of the control. However, during 15-day
205 refrigerated storage, T1 exhibited the highest TA value, which rose from 0.96% on day 0 to
206 1.04% on day 9 and continued increasing to 1.06% on day 15. A similar trend was observed

207 in T2 wherein TA sharply increased from 0.95% on day 0 to 1.02% on day 9, reaching 1.04%
208 on day 15. This increase correlated with the rapid pH decrease during the initial refrigerated
209 storage period (days 0–9). In contrast, T3 and T4 displayed more gradual increases in TA
210 from 0.95% and 0.94% on day 0 to 0.99% and 0.96% on day 15, respectively.

211 Moreover, viable count (Figure 3C) and survival rate (Figure 3D) demonstrated significant
212 differences among the treatment groups during 15-day refrigerated storage ($p < 0.05$). After
213 fermentation (day 0), the viable cell count of JKL2022 remained the same, exhibiting an
214 inoculum size of 7.53 log CFU/mL in T1. However, it increased to 7.93, 7.94, and 8.11 log
215 CFU/mL in T2, T3, and T4 from the initial inoculum of 7.53 log CFU/mL, respectively.
216 Throughout the refrigerated storage period, all groups exhibited a decreasing trend, with T1
217 displaying the most significant decline to a final count of 2.26 log CFU/mL and survival rate
218 of 30%. In contrast, its viability in yogurt supplemented with carbohydrates demonstrated a
219 gradual decline rather than the sharp decrease observed in T1. JKL2022 viability was
220 maintained at 6.06 log CFU/mL and an 80% survival rate on day 6 in T3, while T2 yielded
221 5.40 log CFU/mL and a 72% survival rate. Ultimately, the viability counts of T2 and T3
222 decreased to 3.34 and 3.50 log CFU/mL, with survival rates of 44% and 46% on day 15,
223 respectively. Nonetheless, JKL2022 exhibited the highest survivability in T4, yielding 6.15
224 log CFU/mL and an 82% survival rate on day 9, followed by a decrease to 4.55 log CFU/mL
225 and a 60% survival rate on day 15. This indicates that TOS-added yogurt exhibited the highest
226 JKL2022 survival rate among the four groups.

227

228 Chemical Properties and Probiotic Viability of Cream Cheese

229 JKL2022 viability changes in whey and curds during the cream cheese manufacturing
230 process were analyzed (**Table 2**). The microbial counts of JKL2022 were significantly higher
231 in the curds than in the whey throughout the entire manufacturing process ($p < 0.05$). This

232 suggests that JKL2022 is more extensively distributed in the curds during cream cheese
233 production. Moreover, JKL2022 viability gradually concentrated in the curds, increasing from
234 7.85 log CFU/mL after fermentation to 8.15 log CFU/mL after draining. The final JKL2022
235 microbial counts were concentrated to 8.17 log CFU/mL in the curds after salting from 7.39
236 log CFU/mL in the milk after inoculation.

237 Thereafter, changes in JKL2022 pH, bacterial count, and survivability (%) in cream cheese
238 were monitored during the 15-day refrigerated storage period (**Figure 4**). Overall, pH,
239 bacterial count, and survival rate (%) significantly decreased during refrigerated storage ($p <$
240 0.05). pH decreased from 5.51 after salting (day 0) to 4.96 on day 15 of refrigerated storage
241 (Figure 4A). JKL2022 viability also displayed this decreasing trend during the storage period
242 (Figure 4B). Cell counts decreased from 8.17 log CFU/g on day 0 to 7.74 log CFU/g on day 9,
243 followed by a further decrease to 7.58 log CFU/g on day 15. Even though the microbial
244 counts of JKL2022 declined, its survival rate remained between 102% and 111% throughout
245 refrigerated storage (Figure 4C). This suggests that JKL2022 can maintain relatively high
246 survivability within the cheese matrix during both the manufacturing process and storage
247 period.

248 DISCUSSION

249 This study evaluated the survivability of *B. breve* JKL2022 in three dairy products: whole
250 milk, yogurt, and cream cheese with the aim of developing probiotic dairy products.
251 Preliminary experiments on the ability of JKL2022 to grow in milk and its derivative products
252 were performed using 10% RSM. Most independent studies that utilize milk as a culture
253 medium often add glucose, yeast extract, or their combination to promote LAB growth. In this
254 study, JKL2022 demonstrated favorable growth, fermentation, and CLA production when
255 cultured in 10% RSM supplemented with 0.1% yeast extract or a combination of 0.1% yeast
256 extract and 2.0% glucose. The additional nutritional content derived from these additives is
257 hypothesized to promote the strain's metabolic activity, allowing better proliferation than that
258 in RSM alone. Additionally, the effects of different sterilization methods were comparatively
259 investigated to assess the minimum treatment required for optimal growth and CLA
260 production. The results revealed that both traditional heat treatment and autoclave methods
261 proved to be efficient means of inactivating contaminants and supporting strain growth.
262 However, in terms of CLA production under aerobic conditions, a higher CLA yield was
263 observed in heat-treated RSM than in autoclaved media. Nevertheless, CLA production under
264 anaerobic conditions exhibited similar outcomes. These results verify that JKL2022 can
265 produce CLA in milk-derived products under both aerobic and anaerobic conditions.
266 Considering that dairy products are typically produced under aerobic conditions, this suggests
267 that JKL2022 may significantly contribute to the development of dairy products with
268 enhanced CLA content. Moreover, it was confirmed that significant CLA production occurred
269 only when curd formation (\leq pH 5.0) took place as JKL2022 exhibited a certain level of
270 metabolic activity and growth. This demonstrates a similar result to other reports indicating
271 that bacterial CLA production is correlated with its growth as CLA isomerization serves as a
272 detoxification mechanism. Free LA, which is toxic to bacteria, is converted into less-toxic

273 CLA, thereby protecting the bacterial cells (Jang et al., 2024). Thus, the onset of CLA
274 production is closely linked to bacterial growth, indicating that JKL2022 must achieve a
275 specific growth level to efficiently produce CLA.

276 Moreover, JKL2022 survivability in three dairy products (whole milk, yogurt, and cream
277 cheese) and changes in the chemical characteristics of these products were analyzed. First,
278 this study verified that probiotic whole milk can be successfully developed by applying
279 JKL2022. *B. breve* JKL2022 maintained high viable cell counts of 7.44–7.46 log CFU/mL in
280 whole milk at neutral pH during 15-day refrigerated storage. Moreover, the pH and TA values
281 of whole milk supplemented with JKL2022 aligned with the standards for normal whole milk,
282 with pH and TA values of 6.60–6.80 and 0.14–0.18%, respectively (Tadesse et al., 2023).
283 This indicates that it satisfies the standards for probiotic food, maintaining the minimum
284 viable count of 1×10^6 CFU/mL throughout refrigerated storage without affecting milk
285 quality.

286 Furthermore, the viability of JKL2022 in yogurt samples supplemented with three different
287 carbohydrates surpassed that in the control. This is because the additional carbohydrates
288 served as extra energy sources for JKL2022, enabling longer-lasting metabolic activity
289 (Kamel et al., 2021; Khatami et al., 2022). First, glucose potentially enhances starter culture
290 and JKL2022 growth in yogurts, serving as the fundamental energy source for numerous
291 organisms (Khatami et al., 2022). This effect was evident in T2, which displayed a higher
292 viable cell count (6.32 log CFU/mL) than the control group (4.68 log CFU/mL) on day 3.
293 Next, inulin has been known to promote probiotic viability in dairy products (De Souza
294 Oliveira et al., 2011; Kamel et al., 2021). Although JKL2022 maintained a survival rate >
295 80% until day 6, it still exhibited a decreasing trend over the 15 day-refrigerated storage. This
296 is because inulin affects the growth of both JKL2022 and starter cultures by serving as
297 prebiotics that promote the proliferation of these bacteria (Kamel et al., 2021). This increased

298 bacterial growth leads to a decline in yogurt pH, which subsequently diminishes the viability
299 of JKL2022. In contrast, TOS-supplemented yogurt displayed the highest survivability (>
300 60%) throughout the 15-day refrigerated storage. This is because TOS is a well-known highly
301 selective prebiotic for *Bifidobacterium*, supporting the metabolic activity and growth of
302 JKL2022 during storage (Arapovic et al., 2024). However, JKL2022 viability in all yogurts
303 demonstrated low viability, ranging from 2.26 to 4.55 log CFU/mL on day 15, even though
304 additional energy sources contributed to its enhanced survivability. This result is consistent
305 with that of other studies that evaluated the viability of bifidobacteria in fermented milk or
306 yogurt. Odamaki et al. (2011) observed that the cell counts of six species of *Bifidobacterium*
307 decreased after 14 d of refrigerated storage, ranging from approximately 1.16 to 4.57 log
308 CFU/mL. This decline was attributed to two significant challenges: oxygen exposure and a
309 low pH. To overcome these limitations, methods such as microencapsulation and oxygen
310 scavenging, are necessary to enhance JKL2022 survivability in yogurt (Afzaal et al. 2020;
311 Norouzbeigi et al., 2021).

312 Cheese has recently been considered a better carrier of probiotics than fermented milk and
313 yogurt owing to its physiological characteristics, such as a high pH and buffering capacity
314 (Rolim et al., 2020). This study observed that JKL2022 was mainly distributed in curd during
315 the cream cheese manufacturing process and displayed high viability during refrigerated
316 storage, ranging from 7.58 to 8.17 log CFU/g. This value indicates that JKL2022 maintained
317 higher viability than other *Bifidobacterium* spp. in cheese. For example, a previous study
318 found *B. longum* B1 to survive at 6.30–7.09 log CFU/g in Argentinian Fresco cheese at 5°C
319 for 60 d (Vinderola et al., 2000). In another study, *B. bifidum* BB-02 decreased from an initial
320 inoculum size of 7.00 log CFU/mL to 6.00 log CFU/g after a 56-d ripening period at 12°C in
321 Canestrato Pugliese hard cheese (Corbo et al., 2001). This indicates that JKL2022 can be
322 applied to cream cheese for the development of probiotic cream cheese, as the number of

323 living cells exceeded the minimum value required for probiotic benefits. However, JKL2022
324 viability was affected by a decrease in pH, indicating that JKL2022 is particularly sensitive to
325 acidic conditions.

326 Considering the growing demand for functional foods, developing products enriched with
327 health-beneficial components is important. In this study, we focused on developing probiotic
328 dairy products as functional foods using *B. breve* JKL2022 as a potential probiotic adjunct
329 culture. This study successfully produced probiotic whole milk and cream cheese, which
330 predominantly possess a higher pH than yogurt. To develop probiotic yogurt, further research
331 into applying microencapsulation and oxygen scavengers, which protect *Bifidobacterium* spp.
332 from stress conditions, is warranted. Moreover, we generated concrete evidence suggesting
333 that JKL2022 can produce CLA in milk-derived media when sufficient growth of JKL2022 is
334 achieved with appropriate amounts of substrates, indicating its potential in the development of
335 CLA-enriched dairy products incorporating JKL2022.

336 **REFERENCES**

- 337 Abdi M, Ghaleh HEG, Ranjbar R. 2022. *Lactobacilli* and *bifidobacterium* as anti-
338 atherosclerotic agents. Iran J Basic Med Sci 25:934-946.
- 339 Afzaal M, Saeed F, Ateeq H, Ahmed A, Ahmad A, Tufail T, Ismail Z, Anjum FM. 2020.
340 Encapsulation of *Bifidobacterium bifidum* by internal gelation method to access the
341 viability in cheddar cheese and under simulated gastrointestinal conditions. Food Sci
342 Nutr 8:2739-2747.
- 343 Ali MA, Kamal MM, Rahman MH, Siddiqui MN, Haque MA, Saha KK, Rahman MA. 2022.
344 Functional dairy products as a source of bioactive peptides and probiotics: Current
345 trends and future prospectives. J Food Sci Technol 59:1263-1279.
- 346 Arapović M, Puljić L, Kajić N, Kartalović B, Habschied K, Mastanjević K. 2024. New
347 insights in prebiotic utilization: A systematic review. Processes 12:867.
- 348 Barone M, D'amico F, Brigidi P, Turrone S. 2022. Gut microbiome-micronutrient interaction:
349 The key to controlling the bioavailability of minerals and vitamins? Biofactors
350 48:307-314.
- 351 Basak S, Duttaroy AK. 2020. Conjugated linoleic acid and its beneficial effects in obesity,
352 cardiovascular disease, and cancer. Nutrients 12.
- 353 Corbo MR, Albenzio M, De Angelis M, Sevi A, M. G. 2001. Microbiological and
354 biochemical properties of Canestrato Pugliese hard cheese supplemented with
355 bifidobacteria. J. Dairy Sci. 84(3):551-561.
- 356 De Souza Oliveira RP, Perego P, De Oliveira MN, Converti A. 2011. Effect of inulin as a
357 prebiotic to improve growth and counts of a probiotic cocktail in fermented skim milk.
358 LWT 44:520-523.
- 359 Faghfoori Z, Faghfoori MH, Saber A, Izadi A, Yari Khosroushahi A. 2021. Anticancer effects
360 of bifidobacteria on colon cancer cell lines. Cancer Cell Int 21:258.

361 Gao H, Yang B, Stanton C, Ross RP, Zhang H, Liu Z, Chen H, Chen W. 2020. Characteristics
362 of bifidobacterial conjugated fatty acid and hydroxy fatty acid production and its
363 potential application in fermented milk. LWT 120.

364 Gao J, Li X, Zhang G, Sadiq FA, Simal-Gandara J, Xiao J, Sang Y. 2021. Probiotics in the
365 dairy industry-advances and opportunities. Compr Rev Food Sci Food Saf 20:3937-
366 3982.

367 He BL, Xiong Y, Hu TG, Zong MH, Wu H. 2023. *Bifidobacterium* spp. As functional foods:
368 A review of current status, challenges, and strategies. Crit Rev Food Sci Nutr 63:8048-
369 8065.

370 Jang Y, Elnar AG, Hur SJ, Kim GB. 2024. Factors influencing conjugated linoleic acid
371 content of dairy products: Challenges and strategies. Crit Rev Food Sci Nutr:1-17.

372 Jung MY, Kim G-B, Jang ES, Jung YK, Park SY, Lee BH. 2006. Technical note: Improved
373 extraction method with hexane for gas chromatographic analysis of conjugated
374 linoleic acids. J Dairy Sci 89:90-94.

375 Kamel DG, Hammam ARA, Alsaleem KA, Osman DM. 2021. Addition of inulin to probiotic
376 yogurt: Viability of probiotic bacteria (*Bifidobacterium bifidum*) and sensory
377 characteristics. Food Sci Nutr 9:1743-1749.

378 Khatami SH, Vakili O, Ahmadi N, Soltani Fard E, Mousavi P, Khalvati B, Maleksabet A,
379 Savardashtaki A, Taheri-Anganeh M, Movahedpour A. 2022. Glucose oxidase:
380 Applications, sources, and recombinant production. Biotechnol Appl Biochem 69:939-
381 950.

382 Mei Y, Chen H, Yang B, Zhao J, Zhang H, Chen W. 2022. Research progress on conjugated
383 linoleic acid bio-conversion in *Bifidobacterium*. Int J Food Microbiol 369:109593.

384 Misra S, Pandey P, Mishra HN. 2021. Novel approaches for co-encapsulation of probiotic
385 bacteria with bioactive compounds, their health benefits and functional food product
386 development: A review. Trends Food Sci Tech 109:340-351.

387 Mysore Saiprasad S, Moreno OG, Savaiano DA. 2023. A narrative review of human clinical
388 trials to improve lactose digestion and tolerance by feeding bifidobacteria or galacto-
389 oligosacharides. Nutrients 15:3559.

390 Norouzbeigi S, Vahid-Dastjerdi L, Yekta R, Farhoodi M, Mortazavian AM. 2021. Effects of
391 using different o(2) scavengers on the qualitative attributes of bifidus yogurt during
392 refrigerated storage. Food Res Int 140:109953.

393 Odamaki T, Xiao JZ, Yonezawa S, Yaeshima T, Iwatsuki K. 2011. Improved viability of
394 bifidobacteria in fermented milk by cocultivation with *Lactococcus lactis* subspecies
395 *lactis*. J Dairy Sci 94:1112-1121.

396 Rolim FRL, Freitas Neto OC, Oliveira MEG, Oliveira CJB, Queiroga RCRE. 2020. Cheeses
397 as food matrixes for probiotics: In vitro and in vivo tests. Trends Food Sci Tech
398 100:138-154.

399 Tadesse T, Gure A, Kedir K. 2023. Physicochemical properties and microbial load evaluation
400 of raw cow milks of Jimma town, Ethiopia. Bul Chem Soc Ethiop 37:553-563.


401 Terpou A, Papadaki A, Lappa IK, Kachrimanidou V, Bosnea LA, Kopsahelis N. 2019.
402 Probiotics in food systems: Significance and emerging strategies towards improved
403 viability and delivery of enhanced beneficial value. Nutrients 11:1591.

404 Uebanso T, Shimohata T, Mawatari K, Takahashi A. 2020. Functional roles of b-vitamins in
405 the gut and gut microbiome. Mol Nutr Food Res 64:e2000426.


406 Vinderola CG, Prosello W, Ghiberto D, Reinheimer JA. 2000. Viability of probiotic
407 (*Bifidobacterium*, *Lactobacillus acidophilus* and *Lactobacillus casei*) and nonprobiotic
408 microflora in Argentinian Fresco cheese. J Dairy Sci 83:1905-1911.

409 Vivek K, Mishra S, Pradhan RC, Nagarajan M, Kumar PK, Singh SS, Manvi D, Gowda
410 NAN. 2023. A comprehensive review on microencapsulation of probiotics:
411 Technology, carriers and current trends. *Appl Food Res* 3:100248.
412 Zendeboodi F, Khorshidian N, Mortazavian AM, Da Cruz AG. 2020. Probiotic:
413 Conceptualization from a new approach. *Curr Opin Food Sci* 32:103-123.

ACCEPTED



415
 416 **Figure 1.** Effect of glucose and yeast extract supplementation in 10% RSM media on (A) pH
 417 profile, (B) viability, and (C) CLA conversion activity of *Bifidobacterium breve* JKL2022
 418 incubated under aerobic and anaerobic conditions. A – autoclaved media, HT – heat treated
 419 media. ^{A-D} Different letters indicate significant differences between the means within the same
 420 culture media ($p < 0.05$). ^{a-e} Different letters indicate significant differences between the
 421 means across different culture media ($p < 0.05$).




422

423 **Figure 2.** (A) pH, (B) TA (%), (C) Bacterial counts, and (D) Survivability (%) of
 424 *Bifidobacterium breve* JKL2022 in whole milk during 15-day refrigerated storage.


425 ^{a-b} Different letters indicate significant differences between the means of each storage days (*p*

426 < 0.05).



427

428 **Figure 3.** (A) pH, (B) TA (%), (C) Bacterial counts, and (D) Survivability (%) of
 429 *Bifidobacterium breve* JKL2022 in yogurts during 15-day refrigerated storage. T1; control
 430 without the addition of carbohydrates. T2; yogurts with 2% (w/v) of glucose. T3; yogurts with
 431 2% (w/v) of inulin. T4; yogurts with 2% (w/v) of trans-galactooligosaccharides (TOS).
 432 ^{A-D} Different letters indicate significant differences between the means of different groups on
 433 the same storage day ($p < 0.05$). ^{a-c} Different letters indicate significant differences between
 434 the means of each storage day within the same group ($p < 0.05$).



435

436 **Figure 4.** (A) pH, (B) Bacterial counts, and (C) Survivability (%) of *Bifidobacterium breve*

437 JKL2022 in cream cheese during 15-day refrigerated storage. ^{a-b} Different letters indicate

438 significant differences between the means of each storage days ($p < 0.05$).

439 **Table 1.** Optimization of reconstituted skim milk to support the growth and CLA production
 440 of *Bifidobacterium breve* JKL2022.

Treatment	Base Media	Supplements ^a	
		Glucose	Yeast Extract
RSM	10% RSM	-	-
RSG	10% RSM	2.00%	-
RSY	10% RSM	-	0.10%
RSGY	10% RSM	2.00%	0.10%

441 ^a Supplements were added as % (w/v).

442

443 **Table 2.** The viability of *Bifidobacterium breve* JKL2022 during the manufacturing processes
 444 of cream cheese.

Samples	Log CFU/mL or g	
	Whey	Curds
After fermentation (pH 5.5)	6.89±0.02 ^{Ba}	7.85±0.25 ^{Ab}
After heating	6.68±0.07 ^{Ba}	8.06±0.03 ^{Aab}
After draining	6.81±0.17 ^{Ba}	8.18±0.17 ^{Aa}

445 ^{A-B} A significant difference exists between groups with different letters ($p < 0.05$).

446 ^{a-c} A significant difference exists between manufacturing processes with different letters ($p <$
 447 0.05).

448